Proto Labs heads into its third-quarter report with an unusual setup: Wall Street now expects more profit than the company said it would deliver. After a record second quarter and the first guidance raise of what management had framed as a transformation year, analysts have pushed their earnings estimate to $0.43 per share. That sits just above the top of management's $0.34 to $0.42 range and well above the roughly $0.36 consensus that prevailed when the outlook was issued. The quarter is therefore less about whether the turnaround is real and more about whether it is running faster than management is willing to say.
Revenue expectations look more grounded. The consensus of $148.7 million falls comfortably inside guidance of $145 million to $153 million, slightly below the midpoint, and would represent growth of about 9.8% from $135.4 million a year ago. That is solid but not spectacular, and it implies revenue roughly flat with the second quarter's record $149.3 million. The expected 43% jump in earnings is where the ambition lies, which puts the spotlight squarely on margins. Last quarter, gross margin climbed to 46.8% and adjusted EBITDA margin reached 16.8%, both continuing a steady upward march. Clearing the Street's number likely requires that progress to continue even as SG&A spending rises to fund new sales leadership and other strategic initiatives, something management signaled would remain elevated.
The most important operating test is injection molding. Long the company's laggard, the segment accelerated to nearly 13% constant-currency growth last quarter, up from 3.5% in the first quarter and a decline for all of 2025, helped by larger orders from data-center telecom and aerospace and defense customers. A second straight quarter of double-digit growth would go a long way toward proving that the pivot toward production work and medical certification is producing durable demand rather than a lumpy one-off. A sharp fallback would raise questions about how much of the raised full-year outlook, now $575.8 million to $586.4 million, rests on a few big orders.
Europe is the other swing factor. The region swung to 7.3% growth after several quarters of decline, and its consolidation into a single legal entity on one ERP system went live on July 1, right at the start of this quarter. System cutovers can disrupt ordering and fulfillment, so steady European growth would be a meaningful validation, while any wobble would test patience given that management still describes European profitability as unfinished business. Watch, too, the softer corners of the portfolio: 3D printing slipped into decline, and the third-party network was flat while the company's own factories carried CNC growth. Further network improvement, building on last quarter's rebound in network gross margin to 33.6%, would broaden the recovery.
The market has already rewarded the story. Shares have gained about 9.7% since the last report, outpacing the S&P 500 by more than six points, and at $87.73 the stock trades well above its 200-day average near $72. It has, however, pulled back roughly 12% from its post-earnings peak near $100, and sentiment has cooled noticeably, with bullish readings falling to about 20% from nearly 38% before the prior report. That combination suggests enthusiasm has been tempered even as estimates have climbed.
Ultimately, the report hinges on whether Proto Labs can show that last quarter's broad-based improvement in injection molding, Europe and margins was the start of a trend. Another beat backed by sustained molding strength and a smooth European transition would justify the Street's aggressive earnings bar and keep the door open to a further raise. Anything that looks like a one-quarter spike would leave expectations sitting uncomfortably above management's own math.